Twitter Facebook LinkedIn YouTube

Valeo Pharma Inc. (CSE:VPH) New Listing

Video Platform Video Management Video Solutions Video Player

The company’s strategy is to acquire, primarily through in-licensing or similar arrangements, but also through targeted acquisitions, a diversified portfolio of branded pharmaceutical products for commercialization in Canada.

Additional Information:

Company: Valeo Pharma Inc
Website: http://www.valeopharma.com
Stock Symbol: CSE: VPH
Date Published: Feb 21, 2019
Transcript: Available

Video Transcript:

I’m Megan Edwards for Investmentpitch Media

Valeo Pharma Inc. is one of the latest new listing on the Canadian Securities Exchange, trading under the symbol “VPH”.

Founded in 2003, Valeo Pharma has a long history of successfully commercializing pharmaceutical products in Canada.

The company’s strategy is to acquire, primarily through in-licensing or similar arrangements, but also through targeted acquisitions, a diversified portfolio of branded pharmaceutical products for commercialization in Canada.

With its current focus on the acquisition and distribution of pharmaceuticals that address unmet medical needs in Neurology, such as Parkinson’s disease and movement disorders, Multiple Sclerosis, and Schizophrenia; Woman’s Health, such as assisted fertility; and Hospital products such as pain management, including narcotics, anti-infectives, among others, the company has an impressive portfolio and product pipeline.

With the recent approval by Health Canada of Onstryv, a novel treatment for Parkinson's disease, Valeo Pharma is preparing for the launch of five products in 2019.

According to GlobalData Intelligence Center, the Canadian Pharmaceutical market is set to grow from 2016 levels of $22.6 billion to over $25 billion in 2021.

In 2016, Generic Drugs made up $6.2 billion in sales, but accounted for 70% of all prescriptions, with patented medicines accounting for more than $15 Billion in annual spending.

Steve Saviuk, President and CEO, stated: “This is an exciting time for Valeo Pharma's shareholders, employees and pharmaceutical partners. Following the sale of our dermatology portfolio in 2014 our team has worked extensively on developing the company's new therapeutic areas of focus. The approval by Health Canada of Onstryv for the treatment of Parkinson's disease is a significant milestone for our company. Valeo Pharma is now preparing for Onstryv's commercial launch in the second quarter of calendar 2019. We are also making preparations for the launch of our first prescription product in women's health and three other products in our growing hospital specialty portfolio, including our first product entry into the U.S. Our product pipeline continues to expand reflecting our experienced and diverse regulatory and commercial capabilities. With our upcoming product launches and revenue growth, Valeo Pharma is well positioned for a successful debut on the CSE as a publicly traded specialty pharma company."

The company recently raised gross proceeds of $1.4 million from a non-brokered private placement of convertible debentures.

The convertible debentures were automatically converted into Class "A" shares at an exercise price of $0.40 per share upon approval for listing.

The shares are trading at $0.69.

For more information, please visit the company’s website www.valeopharma.com, contact Steve Saviuk, President and CEO, at 514-693-8830, or by email at saviuk@valeopharma.com.
I’m Megan Edwards for Investmentpitch Media